These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 29485832)

  • 1. Transmembrane Activator and Caml Interactor (Taci) Haploinsufficiency in B-Cell Dysfunction in a Patient with Smith-Magenis Syndrome.
    Karaca E; Atik T; Alpman Durmaz A; Ozkinay F; Cogulu O
    Genet Couns; 2016; 27(2):251-4. PubMed ID: 29485832
    [No Abstract]   [Full Text] [Related]  

  • 2. Transmembrane activator and CAML interactor (TACI) haploinsufficiency results in B-cell dysfunction in patients with Smith-Magenis syndrome.
    Chinen J; Martinez-Gallo M; Gu W; Cols M; Cerutti A; Radigan L; Zhang L; Potocki L; Withers M; Lupski JR; Cunningham-Rundles C
    J Allergy Clin Immunol; 2011 Jun; 127(6):1579-86. PubMed ID: 21514638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TNF receptor superfamily member 13b (TNFRSF13B) hemizygosity reveals transmembrane activator and CAML interactor haploinsufficiency at later stages of B-cell development.
    Romberg N; Virdee M; Chamberlain N; Oe T; Schickel JN; Perkins T; Cantaert T; Rachid R; Rosengren S; Palazzo R; Geha R; Cunningham-Rundles C; Meffre E
    J Allergy Clin Immunol; 2015 Nov; 136(5):1315-25. PubMed ID: 26100089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The C104R mutant impairs the function of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) through haploinsufficiency.
    Lee JJ; Jabara HH; Garibyan L; Rauter I; Sannikova T; Dillon SR; Bram R; Geha RS
    J Allergy Clin Immunol; 2010 Dec; 126(6):1234-41.e2. PubMed ID: 20889194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterozygosity for transmembrane activator and calcium modulator ligand interactor A144E causes haploinsufficiency and pneumococcal susceptibility in mice.
    Jabara HH; Lee JJ; Janssen E; Ullas S; Liadaki K; Garibyan L; Benson H; Sannikova T; Bram R; Hammarstrom L; Cruz AC; Siegel R; Manis J; Malley R; Geha RS
    J Allergy Clin Immunol; 2017 Apr; 139(4):1293-1301.e4. PubMed ID: 27609654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune complex-mediated autoimmunity in a patient With Smith-Magenis syndrome (del 17p11.2).
    Yang J; Chandrasekharappa SC; Vilboux T; Smith AC; Peterson EJ
    J Clin Rheumatol; 2014 Aug; 20(5):291-3. PubMed ID: 25036569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Common variable immunodeficiency: two mutations are better than one.
    La Cava A
    J Clin Invest; 2013 Oct; 123(10):4142-3. PubMed ID: 24051372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transmembrane activator and calcium-modulator and cyclophilin ligand interactor mutations in common variable immunodeficiency.
    Lee JJ; Ozcan E; Rauter I; Geha RS
    Curr Opin Allergy Clin Immunol; 2008 Dec; 8(6):520-6. PubMed ID: 18978466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a novel immunosubversion mechanism mediated by a virologue of the B-lymphocyte receptor TACI.
    Grant JR; Moise AR; Jefferies WA
    Clin Vaccine Immunol; 2007 Jul; 14(7):907-17. PubMed ID: 17538121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The C76R transmembrane activator and calcium modulator cyclophilin ligand interactor mutation disrupts antibody production and B-cell homeostasis in heterozygous and homozygous mice.
    Bacchelli C; Buckland KF; Buckridge S; Salzer U; Schneider P; Thrasher AJ; Gaspar HB
    J Allergy Clin Immunol; 2011 May; 127(5):1253-9.e13. PubMed ID: 21458042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TACI mutation in Good's Syndrome: in search of a genetic basis.
    Sáenz-Cuesta M; Martínez-Pomar N; de Gracia J; Echaniz P; Villegas E; Prada A; Otaegui D; Matamoros N; Cuadrado E
    Clin Immunol; 2012 Oct; 145(1):27-30. PubMed ID: 22922270
    [No Abstract]   [Full Text] [Related]  

  • 12. Increased expression of TACI on NOD B cells results in germinal centre reaction anomalies, enhanced plasma cell differentiation and immunoglobulin production.
    Banday VS; Thyagarajan R; Sundström M; Lejon K
    Immunology; 2016 Nov; 149(3):297-305. PubMed ID: 27444337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TACI-dependent APRIL signaling maintains autoreactive B cells in a mouse model of systemic lupus erythematosus.
    Tran NL; Schneider P; Santiago-Raber ML
    Eur J Immunol; 2017 Apr; 47(4):713-723. PubMed ID: 28267197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Smith-Magenis Syndrome Patients Often Display Antibody Deficiency but Not Other Immune Pathologies.
    Perkins T; Rosenberg JM; Le Coz C; Alaimo JT; Trofa M; Mullegama SV; Antaya RJ; Jyonouchi S; Elsea SH; Utz PJ; Meffre E; Romberg N
    J Allergy Clin Immunol Pract; 2017; 5(5):1344-1350.e3. PubMed ID: 28286158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetics of common variable immunodeficiency: role of transmembrane activator and calcium modulator and cyclophilin ligand interactor.
    Sathkumara HD; De Silva NR; Handunnetti S; De Silva AD
    Int J Immunogenet; 2015 Aug; 42(4):239-53. PubMed ID: 26096648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three different faces of TACI mutations.
    Cekic S; Cicek F; Karali Y; Gorukmez O; Eren E; Kilic SS
    Scand J Immunol; 2020 Jun; 91(6):e12879. PubMed ID: 32160337
    [No Abstract]   [Full Text] [Related]  

  • 17. TACI deficiency impairs sustained Blimp-1 expression in B cells decreasing long-lived plasma cells in the bone marrow.
    Tsuji S; Cortesão C; Bram RJ; Platt JL; Cascalho M
    Blood; 2011 Nov; 118(22):5832-9. PubMed ID: 21984806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of TACI signaling on humoral immunity and autoimmune diseases.
    Zhang Y; Li J; Zhang YM; Zhang XM; Tao J
    J Immunol Res; 2015; 2015():247426. PubMed ID: 25866827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Preparation and characterization of monoclonal antibodies against human transmembrane activator and calcium modulator and cyclophilin ligand interactor].
    Liu Y; Liu XS; Zhu Y; Chen LH; Cao YX; Xu XG; Hu Y; Tian Y; Jin BQ
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2003 Mar; 19(2):168-9. PubMed ID: 15151758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dominant-negative effect of the heterozygous C104R TACI mutation in common variable immunodeficiency (CVID).
    Garibyan L; Lobito AA; Siegel RM; Call ME; Wucherpfennig KW; Geha RS
    J Clin Invest; 2007 Jun; 117(6):1550-7. PubMed ID: 17492055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.